Arcus Biosciences Shares Drop 20% Following Stock Offering and Kidney Cancer Clinical Data
Shares of Arcus Biosciences (RCUS) fell nearly 20% on Wednesday, closing at $19.10. The significant decline follows the company's presentation of new clinical data regarding its lead oncology candidate, casdatifan, which is being tested across various kidney cancer treatment lines. The stock price drop coincides with a recent stock offering by the biopharmaceutical company. Investors appear to be reacting to both the potential dilution from the offering and the market's interpretation of the latest clinical results for its primary drug candidate.